Pediatric Ethics Subcommittee
Executive Summary
Ethics of a National Institutes of Health-supported protocol on leuprolide testing for puberty disorders to be reviewed by FDA's Pediatric Ethics Subcommittee Nov. 15. The protocol was rejected by University of Chicago Hospitals' Institutional Review Board because of risks from leuprolide (TAP's Lupron) to control subjects, FDA says in Oct. 7 1Federal Register notice calling for comments on the protocol. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8:30 a.m...